Download Files:
Lumasiran
$980 – $3,900
Products Details
Product Description
– Lumasiran (ALN-G01), a siRNA product, reduces hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of Primary hyperoxaluria type 1 (PH1)[1][2].
Web ID
– HY-132588
Storage Temperature
– -20°C (Powder, stored under nitrogen, away from moisture)
Shipping
– Blue Ice
Applications
– Metabolism-protein/nucleotide metabolism
Molecular Formula
– C530H712F10N173O320P43S6
References
– [1]Scott LJ, et al. Lumasiran: First Approval. Drugs. 2021;81(2):277-282.|[2]Garrelfs SF, et al. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. N Engl J Med. 2021;384(13):1216-1226.
CAS Number
– 1834610-13-7
Molecular Weight
– 16339.00 (AS: 7631.0 +SS: 8708.0)
Compound Purity
– 95.37
SMILES
– [Lumasiran]
Clinical Information
– Launched
Research Area
– Metabolic Disease
Solubility
– H2O : 100 mg/mL (ultrasonic)
Target
– Small Interfering RNA (siRNA)
Pathway
– Epigenetics
Product type
– Oligonucleotides
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
Related Products
1000 in stock
